Editing Novo Nordisk A/S (section)

== Segments & Key Projects ==
Novo Nordisk operates in three segments:

Diabetes and Obesity care: This segment accounted for 87% of Novo Nordisk's revenue in 2022. The company's diabetes products include insulin, GLP-1 agonists, and oral antidiabetics. Novo Nordisk is the world's leading diabetes care company, with a market share of over 30%.<ref name=":0">https://www.novonordisk.com/investors/investor-highlights.html</ref>

Biopharmaceutical: This segment accounted for 13% of Novo Nordisk's revenue in 2022. The company's biopharm products treat rare blood disorders, rare endocrine disorders, and hormone replacement therapy. Novo Nordisk is a leading company in the rare disease space, with a market share of over 20%.<ref name=":0" />

'''Breakdown of Novo Nordisk's revenue by segment in 2022:''' <ref name=":1">https://www.novonordisk.com/investors/annual-report.html</ref>

[[File:Segment breakdown.png|center|thumb|509x509px]]<u>Diabetes and Obesity care:</u>

* Insulin: $139.5 billion (63%)
* GLP-1 agonists: $40.5 billion (16%)
* Oral antidiabetics: $20.5 billion (9%)

<u>Biopharmaceutical:</u>

* Rare blood disorders: $11.5 billion (5%)
* Rare endocrine disorders: $5.5 billion (2%)
* Hormone replacement therapy: $1.5 billion (1%)
Novo Nordisk's net profit in 2022 was DKK 55.5 billion (US$8.2 billion). The company's strong revenue growth in 2022 was driven by the continued growth of its diabetes products, particularly its GLP-1 agonists. Novo Nordisk also benefited from the launch of its new obesity drug, Wegovy.


'''Revenue Breakdown by Sector'''<ref name=":1" />

In 2022, Novo Nordisk's revenue breakdown by sector was as follows:

* Diabetes Care: 64%
* Obesity & Metabolism: 20%
* Biopharmaceuticals: 16%


'''Novo Nordisk's revenue in 2022 came from the following global markets:'''<ref name=":1" />
* North America: This region accounted for 54% of Novo Nordisk's revenue in 2022. The United States is Novo Nordisk's largest market, accounting for 40% of the company's total revenue.
* Europe: This region accounted for 29% of Novo Nordisk's revenue in 2022. Germany, France, and Italy are Novo Nordisk's largest markets in Europe.
* China: This region accounted for 9% of Novo Nordisk's revenue in 2022. China is the fastest growing market for Novo Nordisk, and the company expects to see continued growth in this market in the coming years.
* Other markets: This region accounted for 8% of Novo Nordisk's revenue in 2022. This includes markets such as Japan, Brazil, and India.
<u>Detailed breakdown of Novo Nordisk's revenue by market in 2022:</u>

[[File:Country breakdown.png|center|thumb|757x757px]]

* North America:
** United States: $90.6 billion (33%)
** Canada: $10.5 billion (4%)

* Europe:
** Germany: $23.2 billion (9%)
** France: $19.2 billion (8%)
** Italy: $16.5 billion (7%)
* China: $15.7 billion (6%)
* Other markets:
** Japan: $10.2 billion (4%)
** Brazil: $7.5 billion (3%)
** India: $5.8 billion (2%)